Clinical Trials Sponsored by Keymed Biosciences Co.Ltd

Total 50 results

Keymed Biosciences Co.Ltd

Not yet recruiting

Single Dose Escalation Study of CM383 in Healthy Volunteers

Alzheimer Disease
Keymed Biosciences Co.Ltd

Not yet recruiting

Study of CM310 in Subjects With Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

China
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
Keymed Biosciences Co.Ltd

Recruiting

Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

IgA Nephropathy

China
Keymed Biosciences Co.Ltd

Recruiting

Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

Healthy

China
Keymed Biosciences Co.Ltd

Recruiting

A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

Atopic Dermatitis

China
Keymed Biosciences Co.Ltd

Recruiting

The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

China
Keymed Biosciences Co.Ltd

Recruiting

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Gastric Cancer | Pancreatic Cancer | Advanced Solid Tumor | Gastroesophageal Junction Adenocarcinoma

China
Keymed Biosciences Co.Ltd

Completed

A Study of CM310 in Subjects With Moderate to Severe Asthma

Asthma

China
Keymed Biosciences Co.Ltd

Active, not recruiting

Study of CM310 in Subjects With Allergic Rhinitis (PHECDA)

Allergic Rhinitis

China
Keymed Biosciences Co.Ltd

Completed

Study of CM310 in Healthy Subjects

Healthy

China
Keymed Biosciences Co.Ltd

Completed

A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects

Asthma

China
Keymed Biosciences Co.Ltd

Completed

Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1)

Chronic Rhinosinusitis (Diagnosis) | Nasal Polyps

China
Keymed Biosciences Co.Ltd

Completed

Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Moderate-to-severe Atopic Dermatitis

China
Keymed Biosciences Co.Ltd

Not yet recruiting

Study on the Treatment of Prurigo Nodularis With Stapokibart Injection

Prurigo Nodularis
Keymed Biosciences Co.Ltd

Not yet recruiting

Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

Chronic Rhinosinusitis With Nasal Polyps

China
Keymed Biosciences Co.Ltd

Not yet recruiting

Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis

Atopic Dermatitis

China
Keymed Biosciences Co.Ltd

Not yet recruiting

Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

Atopic Dermatitis
Keymed Biosciences Co.Ltd

Not yet recruiting

Study of CM310 in Patients With Allergic Rhinitis

Allergic Rhinitis
Keymed Biosciences Co.Ltd

Recruiting

Study of CM326 Injection in Healthy Subjects

Healthy

China
Keymed Biosciences Co.Ltd

Recruiting

Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

China
Keymed Biosciences Co.Ltd

Recruiting

The Study of CM326 in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

China
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM310 in Subjects With Chronic Pruritus

Chronic Pruritus of Unknown Origin
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）

Chronic Rhinosinusitis With Nasal Polyposis
Keymed Biosciences Co.Ltd

Recruiting

Single Ascending Dose Study of CM338 in Healthy Volunteers

Healthy

China
Keymed Biosciences Co.Ltd

Recruiting

The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

China
Keymed Biosciences Co.Ltd

Completed

Single Ascending Dose Study of CM326 in Healthy Volunteers

Asthma

China
Keymed Biosciences Co.Ltd

Not yet recruiting

Study of CM313 in Healthy Subjects

Healthy
Keymed Biosciences Co.Ltd

Not yet recruiting

Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects

Healthy

China
Keymed Biosciences Co.Ltd

Recruiting

The Study of CM326 in Moderate-to-severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

China
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Keymed Biosciences Co.Ltd

Not yet recruiting

Multiple Ascending Dose Study of CM338 in Healthy Volunteers

Healthy Subjects
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Keymed Biosciences Co.Ltd

Recruiting

A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

China
Keymed Biosciences Co.Ltd

Recruiting

A Study of CM350 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Keymed Biosciences Co.Ltd

Recruiting

The Study of CM310 in Patients With Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

China
Keymed Biosciences Co.Ltd

Recruiting

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Lymphoma | Multiple Myeloma

China
Keymed Biosciences Co.Ltd

Active, not recruiting

A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps (DUBHE)

Chronic Rhinosinusitis With Nasal Polyps

China
Keymed Biosciences Co.Ltd

Completed

Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Moderate-to-severe Atopic Dermatitis

China
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

COVID-19

China
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

COVID-19

China
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

COVID-19

China
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198

COVID-19

China
BioSCIENCE GmbH
HeiMed

Completed

Safety and Efficacy of the HA-based Dermal Fillers HYAPROF® SOFT and HYAPROF® BALANCE (PMCF_HYAPROF)

Dermal Filler

Germany
BioSCIENCE GmbH
HeiMed

Completed

Safety and Efficacy of the HA-based Dermal Fillers HYAcorp Lips and Face (PMCF_HYAcorp)

Dermal Filler

Germany
Guangdong Provincial People's Hospital
Shenzhen Chipscreen Biosciences Co.Ltd

Recruiting

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Minimal Residual Disease | AML, Adult

China
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences...

Completed

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Raynaud's Phenomenon Secondary to Systemic Sclerosis

United States
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences...

Completed

Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis

Onychomycosis/Onycholysis and Tinea Pedis

United States
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences...

Unknown

Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

Sexual Dysfunction | Erectile Dysfunction | Secondary Hypogonadism

United States
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute and other collaborators

Active, not recruiting

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Prostate Cancer

United States

Clinical Trials Sponsored by Keymed Biosciences Co.Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations